

TOXICOLOGIC PATHOLOGY

Call for Papers for a Special Issue on: Ocular Pathology and Drug Development



journals.sagepub.com/home/tpx

Editor-in-Chief:

Susan A. Elmore, MS, DVM, DACVP,
DABT, FIATP

Guest Editors:

- Meg Ferrell Ramos, DVM, PhD,
DACVP
- Kenneth A Schafer, DVM, PhD,
DACVP, FIATP
- Steven D. Sorden, DVM, PhD,
DACVP

*The Official Journal of the Society of
Toxicologic Pathology, the British
Society of Toxicological Pathology,
and the European Society of
Toxicologic Pathology*

Toxicologic Pathology is the leading journal in our field with broad influence amongst toxicologic pathologists, industry experts, regulatory authorities, and academicians. In addition, this issue will have interest for ocular and vision scientists and clinicians. Your contribution to this special issue is your opportunity to further the understanding of ocular biology and physiology and to position yourself as a subject matter expert in ocular toxicologic pathology.

Toxicologic Pathology is pleased to announce the publication of a special 2021 issue focusing on Ocular Pathology and Drug Development.

A considerable body of literature exists for the ocular toxicity of small molecules which can often be traced to cellular pathways that result in predictable functional or anatomical changes. Advances in technology and molecular science have resulted in novel therapeutics that often have ocular toxicity that is not well understood. Although new opportunities for the delivery of targeted ocular therapeutics have been created, clinical success has been confounded by unique challenges of drug development for the eye, including the complex structure and organization of multiple tissue matrices specifically designed to function in concert for transparency and visual acuity, and the deviated immune status of the internal ocular environment. A robust literature resource to inform and support diagnosis, interpretation and the understanding of potential translation is lacking.

Articles in this peer reviewed special issue will augment our current understanding of ocular anatomy, physiology, immune responses and pathology in the context of drug development through invited reviews and original manuscripts from subject matter experts. The editors seek manuscripts on a broad range of topics for inclusion: ocular delivery and toxicity of biologics; effects of novel drug delivery devices and vectors on the eye; novel approaches to imaging and quantitative evaluation; ocular biomarkers; ocular pharmacodynamics and toxicokinetic evaluation; ocular toxicity associated with antibody-drug conjugates and other systemically administered therapeutics; ocular considerations for study design, *in-vivo* evaluation and correlative pathology evaluation; practicalities of postmortem collection, preparation, and evaluation; animal models of ocular disease; and case reports.

Abstracts Due: October 1, 2019

Abstracts should be sent to Meg Ramos at: margaret.ramos@abbvie.com

Manuscripts Due: May 1, 2020

